Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
ANTES B+ Clinical Trial
- Conditions
- Interventions
- Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30DDrug: BrimicaDrug: DuaklirDrug: UltibroDrug: UlunarDrug: XoternaDrug: AnoroDrug: LaventairDrug: Spiolto RespimatDrug: YanimoDrug: ForadilDrug: BroncoralDrug: Formoterol stadaDrug: OxisDrug: FormatrisDrug: Formoterol AldoDrug: OnbrezDrug: OslifDrug: HirobrizDrug: StriverdiDrug: BeglanDrug: BetamicanDrug: InaspirDrug: SereventDrug: SoltelDrug: EkliraDrug: BretarisDrug: SeebriDrug: TovanorDrug: EnurevDrug: SpirivaDrug: TavulusDrug: SirkavaDrug: BraltusDrug: GregalDrug: IncruseDrug: Rolufta
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fundacio Privada Mon Clinic Barcelona
- Target Recruit Count
- 1028
- Registration Number
- NCT06282861
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain
U-LABA/ICS Effects on Exercise Performance, Formoterol
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Morten Hostrup, PhD
- Target Recruit Count
- 20
- Registration Number
- NCT06105671
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
Beta2-adrenergic System and Training
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 30
- Registration Number
- NCT04616261
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT04494321
- Locations
- 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2019-10-23
- Target Recruit Count
- 20
- Registration Number
- NCT04137029
- Locations
- 🇷🇺
Kirill Zykov, Moscow, Russian Federation
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03573817
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Spartanburg, South Carolina, United States
Beta2-adrenergic Agonism and Muscle Remodelling
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Morten Hostrup, PhD
- Target Recruit Count
- 72
- Registration Number
- NCT03565302
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
- Conditions
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
- Target Recruit Count
- 393
- Registration Number
- NCT03468790
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03258749
- Locations
- 🇨🇳
Huashan hospital,Fudan university, Shanghai, Shanghai, China
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Kindeva Drug Delivery
- Target Recruit Count
- 1762
- Registration Number
- NCT03015259
- Locations
- 🇺🇸
Clinical Research Consortuim Arizona, Tempe, Arizona, United States
🇺🇸Anaheim Clinical Trials LLC, Anaheim, California, United States
🇺🇸Allergy and Asthma Specialists Medical Group, Huntington Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.